Impact of Urokinase-Type Plasminogen Activator and Its Inhibitor Type 1 on Prognosis in Cervical Cancer of the Uterus

Cancer Research

Volumn 54, Issue 24, 1994, Pages 6539-6548

  Kobayashi, Hiroshi ^a   Fujishiro, Suguru ^a   Terao, Toshihiko ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE;

ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROGNOSIS; UTERINE CERVIX CARCINOMA;

CERVIX NEOPLASMS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LYMPHATIC METASTASIS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; SURVIVAL ANALYSIS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0028639208     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Dano, K. Andreasen, P.A. Grondahl-Hansen, J. Kristensen, P.I. Nielsen, L.S. and Skriver, L. Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res. 44: 139-266, 1985.
2. Liotta, L.A. Rao, C.N. and Barsky, S.H. Tumor invasion and the extracellular matrix. Lab. Invest. 49: 636-649, 1983.
3. Costantini, V. Zacharski, L.R. Memoli, V.A. Kudryk, B.J. Rousseau, S.M. and Stump, D.C. Occurrence of components of fibrinolysis pathways in situ in neoplastic and nonneoplastic human breast tissue. Cancer Res. 51: 354-358, 1991.
4. Oka, T. Ishida, T. Nishino, T. and Sugimachi, K. Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma. Cancer Res. 57; 3522-3525, 1991.
5. Kobayashi, H. Schmitt, M. Goretzki, L. Chucholowski, N. Calvete, J. Kramer, M. Gunzler, W.A. Janicke, F. and Graeff, H. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (pro-uPA). J. Biol. Chem. 266: 5147-5152, 1991.
6. Duffy, M.J. O'Grady, P. Devaney, D. O'Siorain, L. Fennelly, J.L. and Lijnen, H.J. Urokinase plasminogen activator, a marker for aggressive breast carcinoma: preliminary report. Cancer (Phila.), 62: 531-533, 1988.
7. Ossowski, L. Clunie, G. Masucci, M.T. and Blasi, F. In vitro paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J. Cell Biol. 775; 1107-1112, 1991.
8. Janicke, F. Graeff, H. and Schmitt, M. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin. Thromb. Hemost. 17: 303-312, 1991.
9. Hasui, Y. Marutsuka, K. Suzumiya, J. Kitada, S. Osada, Y. and Sumitoshi, A. The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer. Int. J. Cancer. 50: 871-873, 1992.
10. Foekens, J.A. Schmitt, M. van Putten, W.L.J. Peters, H.A. Bontenbal, M. Janicke, F. and Klijn, J.G.M. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res. 52: 6101-6105, 1992.
11. Grondahl-Hansen, J. Ralfkiaer, E. Kirkeby, L.T. Kristensen, P. Lund, L.R. and Dano, K. Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am. J. Pathol. 138: 111-117, 1991.
12. Kohga, S. Harvey, S.R. Weaver, R.M. and Markus, G. Localization of plasminogen activators in human colon cancer by immunoperoxidase staining. Cancer Res. 45: 1778-1796, 1985.
13. Kohga, S. Harvey, S.R. Suzumiya, J. Sumiyoshi, A. and Markus, G. Comparison of the immunohistochemical localization of urokinase in normal and cancerous human colon tissue. Fibrinolysis, 3: 17-22, 1989.
14. Burtin, P. Chavenel, G. Andre-Bougaran, J. and Gentile, A. The plasmin system in human adenocarcinomas and their metastases. A comparative immunofluorescence study. Int. J. Cancer, 39: 170-178, 1987.
15. Quax, P.H.A. van Muijen, G.N.P. Weening-Verhoeff, E.J.D. Lund, L.R. Dano, K. Ruiter, D.J. and Verheijen, J.H. Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activators, its type-1 inhibitor, and urokinase-mediated matrix degradation. J. Cell Biol. 775; 191-199, 1991.
16. Sier, C.F.M. Verspaget, H.W. Griffioen, G. Verheijen, J.H. Quax, P.H.A. Dooijewaard, G. De Bruin, P.A.F. and Lamers, C.B.H.W. Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Gastroenterology, 101: 1522-1528, 1991.
17. Baker, M.S. Bleakley, P. Woodrow, G.C. and Doe, W.F. Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation. Cancer Res. 50: 4676-4684, 1990.
18. Sumiyoshi, K. Serizawa, K. Urano, T. Takada, Y. Takada, A. and Baba, S. Plasminogen activator system in human breast cancer. Int. J. Cancer, 50: 345-348, 1992.
19. van Mourik, J.A. Lawrence, D.A. and Loskutoff, D.J. Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J. Biol. Chem. 259: 14914-14921, 1984.
20. Krishnamurti, C. and Alving, B.M. Plasminogen activator inhibitor type 1: biochemistry and evidence for modulation of fibrinolysis in vivo. Semin. Thromb. Hemost. 18: 67-80, 1992.
21. Hekman, C.M. and Loskutoff, D.J. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J. Biol. Chem. 260: 11581-11587, 1985.
22. Ploug, M. Ronne, E. Behrendt, N. Jensen, A.K. Blasi, F. and Dano, K. Cellular receptor for urokinase plasminogen activator. J. Biol. Chem. 266: 1926-1933, 1991.
23. Wun, T.C., Palmier, M.O. Siegel, N.R. and Smith, C.E. Affinity purification of active plasminogen activator inhibitor-1 (PAI-1) using immobilized anhydrouroki-nase. J. Biol. Chem. 264: 7862-7868, 1989.
24. Burgess, R. Hyde, K. Maguire, P.J. Kelsey, P.R. Lin Yin, J.A. and Geary, C.G. Two-color immunoenzymatic technique using sequential staining by APAAP to evaluate two cell antigens. J. Clin. Pathol. 45: 206-213, 1992.
25. Kobayashi, H. Moniwa, N. Sugimura, M. Shinohara, H. Ohi, H. and Terao, T. Increased cell-surface urokinase in advanced ovarian cancer. Jpn. J. Cancer Res. 84: 633-640, 1993.
26. Kobayashi, H. Ohi, H. Sugimura, M. Shinohara, H. Fujii, T. and Terao, T. Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B. Cancer Res. 52: 3610-3614, 1992.
27. Corti, A. Nolli, M.L. and Cassani, G. Differential detection of single-chain and two-chain urokinase-type plasminogen activator by a new immunoadsorbent-amido-lytic assay (IAA). Thromb. Haemost. 56: 407-410, 1986.
28. Kaplan, E.L. and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53: 457-481, 1958.
29. Gehlsen, E.A. A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika, 52: 203-223, 1965.
30. Peto, R. Pike, M.C. Armittage, P. Breslow, N.E. Cox, D.R. Howard, S.V. Mantel, N. McPherson, K. Peto, J. and Smith, P.G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br. J. Cancer, 35: 1-39, 1977.
31. Ossowski, L. In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase. J. Cell Biol. 107: 2437-2445, 1988.
32. Mignatti, P. Robbins, E. and Rifkin, D.B. Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell, 47: 489-498, 1986.
33. Hearing, V.J. Law, L.W. Corti, A. Appella, E. and Blasi, F. Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res. 48: 1270-1278, 1988.
34. Schlechte, W. Murano, G. and Boyd, D. Examination of the role of the urokinase receptor in human colon cancer mediated laminin degradation. Cancer Res. 49: 6064-6069, 1989.
35. Fujishiro, S. Kobayashi, H. and Terao, T. Urokinase-type plasminogen activator and granulocyte elastase as a predictor for lymph node metastasis in patients with cervical cancer of the uterus. Acta Obstet. Gynaecol. Jpn. 46: 129-136, 1994.
36. Janicke, F. Schmitt, M. Ulm, K. Gossner, W. and Graeff, H. Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet, 2: 1049, 1989.
37. Tsuboi, R. and Rifkin, D.B. Bimodal relationship between invasion of the amniotic membrane and plasminogen activator activity. Int. J. Cancer, 46: 56-60, 1990.
38. Grondahl-Hansen, J. Christensen, I.J. Rosenquist, C. Brunner, N. Mouridsen, H.T. Dano, K. and Blichert-Toft, M. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 53: 2513-2521, 1993.